A glucagon-like peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota

Frontiers in Endocrinology

Volumn 9, Issue MAY, 2018, Pages

  Zhao, Li ^a   Chen, Yi ^a   Xia, Fangzhen ^a   Abudukerimu, Buatikamu ^a   Zhang, Wen ^a   Guo, Yuyu ^a   Wang, Ningjian ^a   Lu, Yingli ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Glucagon like peptide 1; Gut microbiota; Metabolism; Obesity; Type 2 diabetes

Indexed keywords

ADIPONECTIN; CHOLESTEROL; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOTOPE; LEPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT GAIN; BODY WEIGHT LOSS; CONTROLLED STUDY; DIABETIC OBESITY; DIET INDUCED OBESITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; GENE SEQUENCE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GOTO KAKIZAKI RAT; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; LIPID METABOLISM; LIQUID SCINTILLATION COUNTING; MALE; MASS FRAGMENTOGRAPHY; METABOLIC PARAMETERS; MICROBIAL COMMUNITY; NONHUMAN; POLYMERASE CHAIN REACTION; RADIOACTIVITY; RAT; THIN LAYER CHROMATOGRAPHY; WISTAR RAT;

EID: 85047242728     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2018.00233     Document Type: Article

References (42)

1. Bauer PV, Duca FA. Targeting the gastrointestinal tract to treat type 2 diabetes. J Endocrinol (2016) 230:R95-113. doi:10.1530/JOE-16-0056
2. Remely M, Aumueller E, Merold C, Dworzak S, Hippe B, Zanner J, et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene (2014) 537:85-92. doi:10.1016/j.gene.2013.11.081
3. Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia (2010) 53:606-13. doi:10.1007/s00125-010-1662-7
4. Wang L, Li P, Tang Z, Yan X, Feng B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci Rep (2016) 6:33251. doi:10.1038/srep33251
5. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 444:1027-31. doi:10.1038/nature05414
6. Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) (2010) 18:190-5. doi:10.1038/oby.2009.167
7. Aoki R, Kamikado K, Suda W, Takii H, Mikami Y, Suganuma N, et al. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. Sci Rep (2017) 7:43522. doi:10.1038/srep43522
8. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun (2013) 4:1829. doi:10.1038/ncomms2852
9. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes (2012) 61:364-71. doi:10.2337/db11-1019
10. Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC, et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes (Lond) (2015) 39:424-9. doi:10.1038/ijo.2014.153
11. Simon MC, Strassburger K, Nowotny B, Kolb H, Nowotny P, Burkart V, et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diabetes Care (2015) 38:1827-34. doi:10.2337/dc14-2690
12. Vettorazzi JF, Ribeiro RA, Borck PC, Branco RC, Soriano S, Merino B, et al. The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. Metabolism (2016) 65:54-63. doi:10.1016/j.metabol.2015.10.021
13. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 368:1696-705. doi:10.1016/S0140-6736(06)69705-5
14. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (2012) 344:d7771. doi:10.1136/bmj.d7771
15. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 374:1606-16. doi:10.1016/S0140-6736(09)61375-1
16. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest (2014) 124:4223-6. doi:10.1172/JCI78371
17. Basso N, Soricelli E, Castagneto-Gissey L, Casella G, Albanese D, Fava F, et al. Insulin resistance, microbiota, and fat distribution changes by a new model of vertical sleeve gastrectomy in obese rats. Diabetes (2016) 65:2990-3001. doi:10.2337/db16-0039
18. Zhao L, Cang Z, Sun H, Nie X, Wang N, Lu Y. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord (2017) 17:13. doi:10.1186/s12902-017-0165-7
19. Vella A, Rizza RA. Application of isotopic techniques using constant specific activity or enrichment to the study of carbohydrate metabolism. Diabetes (2009) 58:2168-74. doi:10.2337/db09-0318
20. Cani PD, Knauf C. How gut microbes talk to organs: the role of endocrine and nervous routes. Mol Metab (2016) 5:743-52. doi:10.1016/j.molmet.2016.05.011
21. Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S, et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol (2014) 32:834-41. doi:10.1038/nbt.2942
22. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature (2006) 444:1022-3. doi:10.1038/4441022a
23. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem (2013) 288:25088-97. doi:10.1074/jbc. M113.452516
24. Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J (2015) 9:1-15. doi:10.1038/ismej.2014.99
25. Falcinelli S, Rodiles A, Unniappan S, Picchietti S, Gioacchini G, Merrifield DL, et al. Probiotic treatment reduces appetite and glucose level in the zebrafish model. Sci Rep (2016) 6:18061. doi:10.1038/srep18061
26. Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut (2011) 60:1214-23. doi:10.1136/gut.2010.234708
27. Blonde L, Montanya E. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Diabetes Obes Metab (2012) 14(Suppl 2):20-32. doi:10.1111/j.1463-1326.2012.01575.x
28. Cai L, Wu H, Li D, Zhou K, Zou F. Type 2 diabetes biomarkers of human gut microbiota selected via iterative sure independent screening method. PLoS One (2015) 10:e0140827. doi:10.1371/journal.pone.0140827
29. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A (2005) 102:11070-5. doi:10.1073/pnas.0504978102
30. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature (2011) 473:174-80. doi:10.1038/nature09944
31. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature (2013) 500:541-6. doi:10.1038/nature12506
32. Wichmann A, Allahyar A, Greiner TU, Plovier H, Lunden GO, Larsson T, et al. Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe (2013) 14:582-90. doi:10.1016/j.chom.2013.09.012
33. Rey FE, Faith JJ, Bain J, Muehlbauer MJ, Stevens RD, Newgard CB, et al. Dissecting the in vivo metabolic potential of two human gut acetogens. J Biol Chem (2010) 285:22082-90. doi:10.1074/jbc. M110.117713
34. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut (2014) 63:1513-21. doi:10.1136/gutjnl-2014-306928
35. Tap J, Furet JP, Bensaada M, Philippe C, Roth H, Rabot S, et al. Gut microbiota richness promotes its stability upon increased dietary fibre intake in healthy adults. Environ Microbiol (2015) 17:4954-64. doi:10.1111/1462-2920.13006
36. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab (2006) 91:4612-9. doi:10.1210/jc.2006-1009
37. Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest (2014) 124:4473-88. doi:10.1172/JCI75276
38. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology (2007) 148:4965-73. doi:10.1210/en.2006-0153
39. Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology (2014) 155:1280-90. doi:10.1210/en.2013-1934
40. Heppner KM, Kirigiti M, Secher A, Paulsen SJ, Buckingham R, Pyke C, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology (2015) 156:255-67. doi:10.1210/en.2014-1675
41. Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes (2014) 63:1224-33. doi:10.2337/db13-1440
42. Cote CD, Zadeh-Tahmasebi M, Rasmussen BA, Duca FA, Lam TK. Hormonal signaling in the gut. J Biol Chem (2014) 289:11642-9. doi:10.1074/jbc. O114.556068